Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene

NEW YORK, October 14, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Lakeland Industries Inc. (NASDAQ: LAKE), Endo International plc (NASDAQ: ENDP), Actavis plc (NYSE: ACT) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7148-100free.

--
Auxilium Pharmaceuticals Inc. Research Reports
On October 9, 2014, Auxilium Pharmaceuticals Inc. (Auxilium) and Endo International plc (Endo) jointly announced a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a total consideration of around $2.6 billion. As per the deal, Endo will pay $33.25 per share, and Auxilium shareholders will have option to choose cash and stock, all-stock or all-cash consideration. The per share consideration represents a premium of 55% to Auxilium's closing price on September 16, 2014, the day Endo made public its proposal for Auxilium. Auxilium also informed that it terminated its proposed merger agreement with QLT, Inc., immediately before signing agreement with Endo. Following the announcement, shares of Auxilium gained 9.01% to close at $32.44. The full research reports on Auxilium are available to download free of charge at:

http://www.analystsreview.com/Oct-14-2014/AUXL/report.pdf

--
Lakeland Industries Inc. Research Reports
On October 9, 2014, the stock of Lakeland Industries Inc. (Lakeland) climbed 52.50% to end the trading session at $17.72 amid significantly high trading volumes. Shares in Lakeland opened the session at $12.30 and hit an intra-day high of $19.79, with 47.92 million shares changing hands. Moreover, the stock has rallied 183.52% in the last one month. According to a NASDAQ report, the steep rise in Lakeland's stock has come after the death of the first patient diagnosed with the Ebola virus in the U.S. As per the report, rising Ebola fears in the U.S. could translate into strong demand for Lakeland's hazmat suits that healthcare providers wear while treating patients detected with infectious diseases such as Ebola. The full research reports on Lakeland are available to download free of charge at:

http://www.analystsreview.com/Oct-14-2014/LAKE/report.pdf

--
Endo International plc Research Reports
On October 9, 2014, Endo International plc (Endo) announced an agreement to acquire Pennsylvania-based Auxilium Pharmaceuticals, Inc. (Auxilium) for $33.25 per share in a cash and stock transaction, for a total consideration of $2.6 billion. Through this acquisition, Endo expects to expand its pharmaceutical products portfolio and achieve significant cost synergies which will boost the Company's operating margin. Rajiv De Silva, President and CEO of Endo, commented, "We are pleased to have reached this agreement with Auxilium, which we believe will create value for both Endo and Auxilium shareholders, as well as for patients, customers and employees. We intend to leverage Auxilium's leading presence in men's health, as well as our R&D capabilities and financial resources to accelerate the growth of XIAFLEX® and Auxilium's other products." The transaction is expected to close in H1 2015, subject to various approvals. Endo's stock fell 5.94% to close at $66.78. The full research reports on Endo are available to download free of charge at:

http://www.analystsreview.com/Oct-14-2014/ENDP/report.pdf

--
Actavis plc Research Reports
On October 9, 2014, Actavis plc (Actavis) and Ironwood Pharmaceuticals (Ironwood) jointly announced that the linaclotide-related data will be presented during the American College of Gastroenterology 2014 Annual Scientific Meeting in Philadelphia, October 17 through October 22, 2014. The data will be presented via oral and poster presentations. The Company informed that Linaclotide, marketed under the trade name Linzess® in U.S. by the two companies, is a guanylate cyclase‐C (GC‐C) agonist and is indicated for treatment of adults with irritable bowel syndrome (IBS) or chronic idiopathic constipation. The full research reports on Actavis are available to download free of charge at:

http://www.analystsreview.com/Oct-14-2014/ACT/report.pdf

--
Celgene Corporation Research Reports
On October 1, 2014, Celgene Corporation (Celgene) announced that it will host its Q3 2014 earnings conference call on October 23, 2014 at 9 a.m. ET to discuss financial and operational results. The webcast of the call can be accessed via the Company website. On average, analysts polled by Bloomberg Businessweek expect Celgene to report Q3 2014 EPS (pre-exceptional) of $0.95. The full research reports on Celgene are available to download free of charge at:

http://www.analystsreview.com/Oct-14-2014/CELG/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review